CandidPharm · Ningbo Candid Pharmaceutical Co., Ltd. · 宁波嘉安药业有限公司
CATEGORY A · CP-EDOX-01Intermediate

Tert-butyl N-[(1R,2S,5S)-2-Amino-5-(dimethylcarbamoyl) cyclohexyl]carbamate;oxalic acid

叔丁基-N-[(1R,2S,5S)-2-氨基-5-(二甲基氨基甲酰基)环己基]氨基甲酸酯草酸盐
CAS Registry No.
1210348-34-7
Related API
Edoxaban
Molecular Weight
375.42
Product Type
Intermediate

Identification & Structure

Chemical structure of Tert-butyl N-[(1R,2S,5S)-2-Amino-5-(dimethylcarbamoyl) cyclohexyl]carbamate;oxalic acid
2D Structure

CC(C)(C)OC(=O)N[C@@H]1C[C@H](CC[C@@H]1N)C(=O)N(C)C.C(=O)(C(=O)O)O

Product CodeCP-EDOX-01
Product TypeIntermediate
CAS Number1210348-34-7
Molecular FormulaC16H29N3O7
Molecular Weight375.42
IUPAC Nametert-butyl N-[(1R,2S,5S)-2-amino-5-(dimethylcarbamoyl)cyclohexyl]carbamate;oxalic acid
SMILESCC(C)(C)OC(=O)N[C@@H]1C[C@H](CC[C@@H]1N)C(=O)N(C)C.C(=O)(C(=O)O)O
InChIKeyIERZZGXDUZIMSC-PBDVDRNWSA-N
PubChem CID46913548
Quality ParametersRequest current specification and available batch documentation

Related API

Listed in our catalog as an intermediate related to Edoxaban.

Specifications and available documentation are reviewed against your project requirements. Availability and lead time are confirmed for each enquiry, taking current stock and production schedules into account.

Direct Inquiries

Request a Quote & Documents

Tell us the quantity, specification and destination. We will reply by email with pricing, lead time and the documents available.

· We will reply by email
· Mutual NDA available on request

Documents on Request

Request current specification and available batch documentation. We will confirm which TDS, SDS, CoA and analytical materials can be shared for this product.

Patent Notice

Supply is reviewed against the destination, patent status and intended use. Products are not offered where the transaction would infringe valid patents or supplementary protection certificates. Where applicable, regulatory-development activities may fall within the Bolar exemption under Article 10(6) of EU Directive 2001/83/EC, as amended by Directive 2004/27/EC, or 35 U.S.C. § 271(e)(1). These provisions have specific conditions; research use alone does not establish an exemption. Buyers must confirm applicable requirements for their jurisdiction and project before ordering. Commercial supply in protected territories requires an applicable legal basis.

Product-specific evaluation

Oxalate salt and stereochemistry

  • Confirm the supplied salt form and salt ratio.
  • Review stereochemical identity and the applicable assay/impurity methods.
TDS
Availability to be confirmed
SDS
Availability to be confirmed
Batch CoA
Availability to be confirmed
Analytical evidence
Availability to be confirmed

These are evaluation topics, not approved specifications. Request the current documents for this material. Sample batch, quantity and delivery arrangements are confirmed for your request.